{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:26Z","timestamp":1788570506637,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vedolizumab (VDZ), a humanised monoclonal antibody against a4\u00df7\u2010integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid\u2010to long\u2010term efficacy of VDZ using real\u2010life data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Our study aimed to determine the efficacy of VDZ in patients with IBD with and without prior exposure to anti\u2010tumour necrosis factor (TNF) treatments in a real\u2010life setting. Furthermore, we investigated confounding factors influencing the remission to VDZ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients participating in the Swiss IBD Cohort Study were included in this study. Remission was defined as calprotectin less than 200\u00a0mg\/kg stool and\/or mucosal healing determined by endoscopy. End points were determined between Months 4 and 8 (T1) and between Months 12 and 16 (T2) after VDZ induction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Remission was reported in 50.5% (110\/218) of patients in T1 (48.7% Crohn's disease [CD] and 52.5% ulcerative colitis [UC]) and 46.8% (102\/218) in T2 (47% CD and 46.5% UC). In UC patients, a significantly higher remission rate was achieved in T2 among anti\u2010TNF\u2010naive patients (57.7%) compared to anti\u2010TNF\u2010experienced patients (34.7%; <jats:italic>p\u00a0=\u00a0<\/jats:italic>0.02; odds ratio\u00a0=\u00a00.39, 95% confidence interval: 0.17\u20130.87). In patients with CD, no difference could be seen in either evaluation interval. Multivariable analysis showed that disease duration significantly influenced remission rates among UC patients. A late response to VDZ therapy with an achievement of remission in T2 was seen in a fifth of all patients (CD: 21.7%, UC: 20.8%). VDZ treatment was stopped in a third of all patients (31.8%) due to nonresponse, adverse events or aggravation of extra\u2010intestinal manifestations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a real\u2010life national cohort setting, VDZ induced remission in more than half of IBD patients. Previous treatment with anti\u2010TNF agents was associated with a significant lower efficacy of VDZ in UC but not in CD patients.<\/jats:p><\/jats:sec>","DOI":"10.1177\/2050640620965106","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T06:56:12Z","timestamp":1605682572000},"page":"398-406","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors influencing the outcome of vedolizumab treatment: Real\u2010life data with objective outcome measurements"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-3506","authenticated-orcid":false,"given":"Orla","family":"Mader","sequence":"first","affiliation":[{"name":"Crohn\u2010Colitis Centre  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-5235","authenticated-orcid":false,"given":"Pascal","family":"Juillerat","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Clinic for Visceral Surgery and Medicine Bern University Hospital  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Z\u00fcrich University Hospital  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Michetti","sequence":"additional","affiliation":[{"name":"Clinique de la Source  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Hruz","sequence":"additional","affiliation":[{"name":"University Centre for Gastrointestinal and Liver Diseases Clarunis St Clara Hospital and University Hospital Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2208-966X","authenticated-orcid":false,"given":"Valerie","family":"Pittet","sequence":"additional","affiliation":[{"name":"University of Lausanne Institute of Social and Preventive Medicine  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Z\u00fcrich University Hospital  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Zahnd\u2010Straumann","sequence":"additional","affiliation":[{"name":"Centerview GmbH and Swiss IBDnet  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Seibold","sequence":"additional","affiliation":[{"name":"Crohn\u2010Colitis Centre  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501930"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz057"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001395"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz095"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.04.040"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13813"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04130.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001039"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz137"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx143"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyy298"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn180"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1480-0"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15294"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.07.007"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx021"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy171"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14548"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)31488-9"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.09.035"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001071"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225572"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165435"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2018.05.006"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640620965106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640620965106","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640620965106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T21:41:47Z","timestamp":1693604507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640620965106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/2050640620965106"],"URL":"https:\/\/doi.org\/10.1177\/2050640620965106","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}